Within a few years, Jim Johnsen and Delaney Van Riper may be among the first to benefit from CRISPR-Cas9 gene editing, a breakthrough that has already revolutionized biology research and promises to resurrect gene therapy.
Within a few years, Jim Johnsen and Delaney Van Riper may be among the first to benefit from CRISPR-Cas9 gene editing, a breakthrough that has already revolutionized biology research and promises to resurrect gene therapy.